August 17, 2020
Teva, Cipla Appear to Settle Generic Delay Suit Over Sensipar
Generate PDF
To read complete article visit Bloomberg Law (subscription required)
Cipla Ltd. dropped an antitrust lawsuit against Teva Pharmaceutical Industries Ltd., following an apparent settlement of claims in Delaware federal court that Teva stopped selling its generic version of Amgen Inc.'s blockbuster calcium reducer Sensipar because of an anti-competitive patent deal.
Contacts
Stay Up To Date With Our Insights
See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe